Versartis Garners $20,000,000 Series D Financing Round

  • Feed Type
  • Date
    10/8/2013
  • Company Name
    Versartis
  • Mailing Address
    275 Shoreline Drive Mountain View, CA 94065
  • Company Description
    Versartis is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis has licensed the rights to three products (VRS-826, VRS-859, and VRS-317) from Amunix.
  • Website
    http://www.versartis.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $20,000,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    The proceeds from this financing will primarily be used to prepare for an international Phase 3 pediatric trial of VRS-317, the company’s proprietary long-acting recombinant human growth hormone (rhGH) for the treatment of growth hormone deficiency (GHD).
  • M&A Terms
  • Venture Investor
    Sofinnova Ventures
  • Venture Investor
    Advent Venture Partners
  • Venture Investor
    Aisling Capital
  • Venture Investor
    Index Ventures
  • Venture Investor
    New Leaf Venture Partners
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.